Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Work In Process (2019 - 2025)

Historic Work In Process for Protalix BioTherapeutics (PLX) over the last 8 years, with Q3 2025 value amounting to $5.4 million.

  • Protalix BioTherapeutics' Work In Process fell 5628.93% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year decrease of 5628.93%. This contributed to the annual value of $11.2 million for FY2024, which is 2418.55% up from last year.
  • Protalix BioTherapeutics' Work In Process amounted to $5.4 million in Q3 2025, which was down 5628.93% from $8.1 million recorded in Q2 2025.
  • Protalix BioTherapeutics' Work In Process' 5-year high stood at $12.3 million during Q3 2024, with a 5-year trough of $1.5 million in Q1 2023.
  • Over the past 5 years, Protalix BioTherapeutics' median Work In Process value was $3.5 million (recorded in 2021), while the average stood at $5.9 million.
  • Per our database at Business Quant, Protalix BioTherapeutics' Work In Process surged by 49810.83% in 2024 and then plummeted by 5628.93% in 2025.
  • Protalix BioTherapeutics' Work In Process (Quarter) stood at $3.3 million in 2021, then decreased by 17.9% to $2.7 million in 2022, then skyrocketed by 238.13% to $9.1 million in 2023, then increased by 24.19% to $11.2 million in 2024, then tumbled by 52.38% to $5.4 million in 2025.
  • Its last three reported values are $5.4 million in Q3 2025, $8.1 million for Q2 2025, and $8.0 million during Q1 2025.